Pharmacological and dietary agents for colorectal cancer chemoprevention: Effects on polyamine metabolism (Review)

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 1802-1812

  Linsalata, Michele ^a   Orlando, Antonella ^a   Ruso, Francesco ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Chemoprevention; Colorectal cancer; Difluoromethylornithine; Flavonoids; Polyamines; Probiotics; Resveratrol

Indexed keywords

ARGININE; CATECHIN; DIOSMIN; DNA TOPOISOMERASE; EPICATECHIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVONOID; GENISTEIN; HESPERIDIN; ORNITHINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHYTOESTROGEN; POLYAMINE; PROCYANIDIN; PROTEIN TYROSINE KINASE; PUTRESCINE; RESVERATROL; SPERMIDINE; SULINDAC; ANTINEOPLASTIC AGENT; ORNITHINE DECARBOXYLASE; SPERMINE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; CANCER RISK; CARDIOVASCULAR DISEASE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON CARCINOGENESIS; COLORECTAL CANCER; DIETARY INTAKE; FAMILY HISTORY; FUNCTIONAL FOOD; GENOTYPE; GLUTATHIONE METABOLISM; HUMAN; NONHUMAN; NUTRITIONAL PARAMETERS; PLANT PRODUCT; POLYAMINE METABOLISM; REVIEW; TEA; CELL TRANSFORMATION; COLORECTAL NEOPLASMS; DIET THERAPY; DRUG EFFECTS; METABOLISM;

ANTICARCINOGENIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CHEMOPREVENTION; COLORECTAL NEOPLASMS; HUMANS; ORNITHINE DECARBOXYLASE; PUTRESCINE; SPERMIDINE; SPERMINE;

EID: 84907222928     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2597     Document Type: Review

References (122)

1. Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3: 768-780, 2003.
2. Casero RA Jr and Marton LJ: Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov 6: 373-390, 2007.
3. Ramani D, De Bandt JP and Cynober L: Aliphatic polyamines in physiology and diseases. Clin Nutr 33: 14-22, 2014.
4. Thomas T and Thomas TJ: Polyamines in cell growth and cell death: Molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58: 244-258, 2001.
5. Rothenburg S, Koch-Nolte F, Rich A and Haag F: A polymorphic dinucleotide repeat in the rat nucleolin gene forms Z-DNA and inhibits promoter activity. Proc Natl Acad Sci USA 98: 8985-8990, 2001.
6. Iacomino G, Picariello G and D'Agostino L: DNA and nuclear aggregates of polyamines. Biochim Biophys Acta 1823: 1745-1755, 2012.
7. Igarashi K and Kashiwagi K: Modulation of cellular function by polyamines. Int J Biochem Cell Biol 42: 39-51, 2010.
8. Pegg AE and Casero RA Jr: Current status of the polyamine research field. Methods Mol Biol 720: 3-35, 2011.
9. Pegg AE: Mammalian polyamine metabolism and function. IUBMB Life 61: 880-894, 2009.
10. Coffino P: Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol 2: 188-194, 2001.
11. Bachrach U: Polyamines and cancer: Minireview article. Amino Acids 26: 307-309, 2004.
12. Linsalata M, Caruso MG, Leo S, Guerra V, D'Attoma B and Di Leo A: Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res 22: 2465-2469, 2002.
13. Linsalata M, Giannini R, Notarnicola M and Cavallini A: Peroxisome proliferator-Activated receptor gamma and spermidine/spermine N1-Acetyltransferase gene expressions are significantly correlated in human colorectal cancer. BMC Cancer 6: 191, 2006.
14. Shantz LM and Levin VA: Regulation of ornithine decarboxylase during oncogenic transformation: Mechanisms and therapeutic potential. Amino Acids 33: 213-223, 2007.
15. Erdman SH, Ignatenko NA, Powell MB, et al: APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis 20: 1709-1713, 1999.
16. Casero RA and Pegg AE: Polyamine catabolism and disease. Biochem J 421: 323-338, 2009.
17. Palmer AJ and Wallace HM: The polyamine transport system as a target for anticancer drug development. Amino Acids 38: 415-422, 2010.
18. Thompson PA and Gerner EW: Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol 3: 369-382, 2009.
19. Pegg AE: Regulation of ornithine decarboxylase. J Biol Chem 281: 14529-14532, 2006.
20. Xiao L and Wang J-Y: Posttranscriptional regulation of gene expression in epithelial cells by polyamines. Methods Mol Biol 720: 67-79, 2011.
21. Ignatenko NA, Babbar N, Mehta D, Casero RA Jr and Gerner EW: Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog 39: 91-102, 2004.
22. Linsalata M, Notarnicola M, Caruso MG, Di Leo A, Guerra V and Russo F: Polyamine biosynthesis in relation to K-ras and p-53 mutations in colorectal carcinoma. Scand J Gastroenterol 39: 470-477, 2004.
23. Notarnicola M, Linsalata M, Caruso MG, et al: Genetic and biochemical changes in colorectal carcinoma in relation to morphologic characteristics. Oncol Rep 10: 1987-1991, 2003.
24. Babbar N and Gerner EW: Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res 188: 49-64, 2011.
25. Seiler N: Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 1. Selective enzyme inhibitors. Curr Drug Targets 4: 537-564, 2003.
26. Laukaitis CM and Gerner EW: DFMO: Targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol 25: 495-506, 2011.
27. Gerner EW and Meyskens FL Jr: Polyamines and cancer: Old molecules, new understanding. Nat Rev Cancer 4: 781-792, 2004.
28. Love RR, Carbone PP, Verma AK, et al: Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst 85: 732-737, 1993.
29. Levin VA, Uhm JH, Jaeckle KA, et al: Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res 6: 3878-3884, 2000.
30. Leveque J, Burtin F, Catros-Quemener V, Havouis R and Moulinoux JP: The gastrointestinal polyamine source depletion enhances DFMO induced polyamine depletion in MCF-7 human breast cancer cells in vivo. Anticancer Res 18: 2663-2668, 1998.
31. Meyskens FL Jr and Gerner EW: Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res 5: 945-951, 1999.
32. Gerner EW: Cancer chemoprevention locks onto a new polyamine metabolic target. Cancer Prev Res (Phila) 3: 125-127, 2010.
33. Love RR, Jacoby R, Newton MA, et al: A randomized, placebocontrolled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev 7: 989-992, 1998.
34. Meyskens FL Jr, Gerner EW, Emerson S, et al: Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst 90: 1212-1218, 1998.
35. Flossmann E and Rothwell PM: Effect of aspirin on long-Yerm risk of colorectal cancer: Consistent evidence from randomised and observational studies. Lancet 369: 1603-1613, 2007.
36. Lawson KR, Ignatenko NA, Piazza GA, Cui H and Gerner EW: Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarkers Prev 9: 1155-1162, 2000.
37. Gerner EW and Meyskens FL Jr: Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res 15: 758-761, 2009.
38. Jacoby RF, Cole CE, Tutsch K, et al: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res 60: 1864-1870, 2000.
39. Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H and Gerner EW: Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer 60 (Suppl 1): 30-35, 2008.
40. Thompson PA, Wertheim BC, Zell JA, et al: Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology 139: 797-805, 2010.
41. Meyskens FL Jr, McLaren CE, Pelot D, et al: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: A randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila) 1: 32-38, 2008.
42. Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW and Meyskens FL: Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila) 2: 209-212, 2009.
43. Zell JA, Ziogas A, Ignatenko N, et al: Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res 15: 6208-6216, 2009.
44. Martinez ME, O'Brien TG, Fultz KE, et al: Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA 100: 7859-7864, 2003.
45. Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ and Houlston RS: Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res 14: 2303-2309, 2008.
46. Jell J, Merali S, Hensen ML, et al: Genetically altered expression of spermidine/spermine N1-Acetyltransferase affects fat metabolism in mice via acetyl-CoA. J Biol Chem 282: 8404-8413, 2007.
47. Jacobs ET, Ahnen DJ, Ashbeck EL, et al: Association between body mass index and colorectal neoplasia at follow-up colonoscopy: A pooling study. Am J Epidemiol 169: 657-666, 2009.
48. Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW and Meyskens FL: Role of obesity in a randomized placebocontrolled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas. Cancer Causes Control 23: 1739-1744, 2012.
49. Wallace HM and Fraser AV: Inhibitors of polyamine metabolism: Review article. Amino Acids 26: 353-365, 2004.
50. Niiranen K, Pietila M, Pirttila TJ, et al: Targeted disruption of spermidine/spermine N1-Acetyltransferase gene in mouse embryonic stem cells. Effects on polyamine homeostasis and sensitivity to polyamine analogues. J Biol Chem 277: 25323-25328, 2002.
51. Battaglia V, DeStefano Shields C, Murray-Stewart T and Casero RA Jr: Polyamine catabolism in carcinogenesis: Potential targets for chemotherapy and chemoprevention. Amino Acids 46: 511-519, 2014.
52. Seiler N: Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect. Part 2. Structural analogues and derivatives. Curr Drug Targets 4: 565-585, 2003.
53. Wallace HM and Niiranen K: Polyamine analogues -An update. Amino Acids 33: 261-265, 2007.
54. Belting M, Borsig L, Fuster MM, et al: Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci USA 99: 371-376, 2002.
55. Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U and Faivre J: Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: A randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet 356: 1300-1306, 2000.
56. Delzenne NM and Williams CM: Prebiotics and lipid metabolism. Curr Opin Lipidol 13: 61-67, 2002.
57. Food and Agriculture Organization of the United Nations and World Health Organization: Probiotics in food: Health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations, World Health Organization, Rome, 2006.
58. Boesten RJ and de Vos WM: Interactomics in the human intestine: Lactobacilli and Bifidobacteria make a difference. J Clin Gastroenterol 42 (Suppl 3): S163-S167, 2008.
59. Quigley EM: Gut bacteria in health and disease. Gastroenterol Hepatol (NY) 9: 560-569, 2013.
60. Riezzo G, Orlando A, D'Attoma B, et al: Randomised clinical trial: Efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation -A double-blind, controlled, crossover study. Aliment Pharmacol Ther 35: 441-450, 2012.
61. Valerio F, de Candia S, Lonigro SL, et al: Role of the probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes in influencing faecal bacteria and biochemical parameters in human subjects. J Appl Microbiol 111: 155-164, 2011.
62. Sisto A and Lavermicocca P: Suitability of a probiotic Lactobacillus paracasei strain as a starter culture in olive fermentation and development of the innovative patented product 'probiotic table olives'. Front Microbiol 3: 174, 2012.
63. Ishikawa H, Akedo I, Otani T, et al: Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 116: 762-767, 2005.
64. Zeng H, Lazarova DL and Bordonaro M: Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J Gastrointest Oncol 6: 41-51, 2014.
65. Kulkarni N and Reddy BS: Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc Soc Exp Biol Med 207: 278-283, 1994.
66. Boleij A and Tjalsma H: Gut bacteria in health and disease: A survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc 87: 701-730, 2012.
67. Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N and Reddy BS: Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis 18: 833-841, 1997.
68. Di Marzio L, Russo FP, D'Alo S, et al: Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities. Nutr Cancer 40: 185-196, 2001.
69. Linsalata M, Russo F, Berloco P, et al: The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa. Helicobacter 9: 165-172, 2004.
70. Famularo G, Perluigi M, Pieluigi M, Coccia R, Mastroiacovo P and De Simone C: Microecology, bacterial vaginosis and probiotics: Perspectives for bacteriotherapy. Med Hypotheses 56: 421-430, 2001.
71. Orlando A, Messa C, Linsalata M, Cavallini A and Russo F: Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacol Immunotoxicol 31: 108-116, 2009.
72. Buts JP and De Keyser N: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci 51: 1485-1492, 2006.
73. Linsalata M, Russo F, Berloco P, et al: Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. In Vivo 19: 989-995, 2005.
74. Matsumoto M and Benno Y: Consumption of Bifidobacterium lactis LKM512 yogurt reduces gut mutagenicity by increasing gut polyamine contents in healthy adult subjects. Mutat Res 568: 147-153, 2004.
75. Cederroth CR and Nef S: Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol 304: 30-42, 2009.
76. Thompson LU, Robb P, Serraino M and Cheung F: Mammalian lignan production from various foods. Nutr Cancer 16: 43-52, 1991.
77. Albini A, Rosano C, Angelini G, et al: Exogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptors. Curr Med Chem 21: 1129-1145, 2014.
78. Cassidy A: Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res 73: 120-126, 2003.
79. Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A and Harper P: Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr 136: 3046-3053, 2006.
80. Lechner D, Kállay E and Cross HS: Phytoestrogens and colorectal cancer prevention. Vitam Horm 70: 169-198, 2005.
81. Hawrylewicz EJ, Zapata JJ and Blair WH: Soy and experimental cancer: Animal studies. J Nutr 125: 698S-708S, 1995.
82. Linsalata M, Messa C, Russo F, Cavallini A and Di Leo A: Estrogen receptors and polyamine levels in human gastric carcinoma. Scand J Gastroenterol 29: 67-70, 1994.
83. Russo F, Linsalata M, Messa C, et al: Polyamines and estrogen-receptor concentrations in human colorectal carcinomas. Ital J Gastroenterol 24: 8-12, 1992.
84. Cross HS, Kallay E, Lechner D, Gerdenitsch W, Adlercreutz H and Armbrecht HJ: Phytoestrogens and vitamin D metabolism: A new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr 134: 1207S-1212S, 2004.
85. Booth C, Hargreaves DF, Hadfield JA, McGown AT and Potten CS: Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. Br J Cancer 80: 1550-1557, 1999.
86. Li HQ, Luo Y and Qiao CH: The mechanisms of anticancer agents by genistein and synthetic derivatives of isoflavone. Mini Rev Med Chem 12: 350-362, 2012.
87. Shon YH, Park SD and Nam KS: Effective chemopreventive activity of genistein against human breast cancer cells. J Biochem Mol Biol 39: 448-451, 2006.
88. Linsalata M, Russo F, Notarnicola M, et al: Effects of genistein on the polyamine metabolism and cell growth in DLD-1 human colon cancer cells. Nutr Cancer 52: 84-93, 2005.
89. Tanaka T, Makita H, Kawabata K, et al: Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis 18: 957-965, 1997.
90. Au A, Li B, Wang W, Roy H, Koehler K and Birt D: Effect of dietary apigenin on colonic ornithine decarboxylase activity, aberrant crypt foci formation, and tumorigenesis in different experimental models. Nutr Cancer 54: 243-251, 2006.
91. Linsalata M, Orlando A, Messa C, Refolo MG and Russo F: Quercetin inhibits human DLD-1 colon cancer cell growth and polyamine biosynthesis. Anticancer Res 30: 3501-3507, 2010.
92. Gosse F, Roussi S, Guyot S, et al: Potentiation of apple procyanidin-Yriggered apoptosis by the polyamine oxidase inactivator MDL 72527 in human colon cancer-derived metastatic cells. Int J Oncol 29: 423-428, 2006.
93. Ibanez C, Simo C, Garcia-Canas V, Gomez-Martinez A, Ferragut JA and Cifuentes A: CE/LC-MS multiplatform for broad metabolomic analysis of dietary polyphenols effect on colon cancer cells proliferation. Electrophoresis 33: 2328-2336, 2012.
94. Wallerath T, Deckert G, Ternes T, et al: Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation 106: 1652-1658, 2002.
95. Sengottuvelan M, Senthilkumar R and Nalini N: Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim Biophys Acta 1760: 1175-1183, 2006.
96. Wolter F and Stein J: Resveratrol enhances the differentiation induced by butyrate in caco-2 colon cancer cells. J Nutr 132: 2082-2086, 2002.
97. Schneider Y, Vincent F, Duranton B, et al: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85-91, 2000.
98. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N and Raul F: Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 39: 102-107, 2001.
99. Wolter F, Turchanowa L and Stein J: Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis 24: 469-474, 2003.
100. Ulrich S, Loitsch SM, Rau O, et al: Peroxisome proliferator-Activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 66: 7348-7354, 2006.
101. Wolter F, Ulrich S and Stein J: Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in colorectal cancer: Key role of polyamines? J Nutr 134: 3219-3222, 2004.
102. Henning SM, Wang P, Abgaryan N, et al: Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res 57: 483-493, 2013.
103. Yang CS, Li G, Yang Z, Guan F, Chen A and Ju J: Cancer prevention by tocopherols and tea polyphenols. Cancer Lett: Feb 8, 2013 (Epub ahead of print).
104. Kumazaki M, Noguchi S, Yasui Y, et al: Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells. J Nutr Biochem 24: 1849-1858, 2013.
105. Melgarejo E, Urdiales JL, Sanchez-Jimenez F and Medina MA: Targeting polyamines and biogenic amines by green tea epigallocatechin-3-gallate. Amino Acids 38: 519-523, 2010.
106. Bachrach U and Wang YC: Cancer therapy and prevention by green tea: Role of ornithine decarboxylase. Amino Acids 22: 1-13, 2002.
107. Paul B, Hayes CS, Kim A, Athar M and Gilmour SK: Elevated polyamines lead to selective induction of apoptosis and inhibition of tumorigenesis by (-)-epigallocatechin-3-gallate (EGCG) in ODC/Ras transgenic mice. Carcinogenesis 26: 119-124, 2005.
108. Chung JY, Huang C, Meng X, Dong Z and Yang CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-Yransformed cells: Structure-Activity relationship and mechanisms involved. Cancer Res 59: 4610-4617, 1999.
109. Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM and Mukhtar H: Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res 60: 5125-5133, 2000.
110. Milovic V, Turchanowa L, Stein J and Caspary WF: Transepithelial transport of putrescine across monolayers of the human intestinal epithelial cell line, Caco-2. World J Gastroenterol 7: 193-197, 2001.
111. Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW and Meyskens FL Jr: Development of a polyamine database for assessing dietary intake. J Am Diet Assoc 107: 1024-1027, 2007.
112. Loser C, Eisel A, Harms D and Folsch UR: Dietary polyamines are essential luminal growth factors for small intestinal and colonic mucosal growth and development. Gut 44: 12-16, 1999.
113. Seiler N, Sarhan S, Grauffel C, Jones R, Knodgen B and Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res 50: 5077-5083, 1990.
114. Muth A, Madan M, Archer JJ, Ocampo N, Rodriguez L and Phanstiel O: Polyamine transport inhibitors: Design, synthesis, and combination therapies with difluoromethylornithine. J Med Chem 57: 348-363, 2014.
115. Ignatenko NA, Besselsen DG, Roy UK, et al: Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Nutr Cancer 56: 172-181, 2006.
116. Yerushalmi HF, Besselsen DG, Ignatenko NA, et al: Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Mol Carcinog 45: 764-773, 2006.
117. Gerner EW: Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models. Biochem Soc Trans 35: 322-325, 2007.
118. Ignatenko NA, Gerner EW and Besselsen DG: Defining the role of polyamines in colon carcinogenesis using mouse models. J Carcinog 10: 10, 2011.
119. Zell JA, Ignatenko NA, Yerushalmi HF, et al: Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer 120: 459-468, 2007.
120. Vargas AJ, Wertheim BC, Gerner EW, Thomson CA, Rock CL and Thompson PA: Dietary polyamine intake and risk of colorectal adenomatous polyps. Am J Clin Nutr 96: 133-141, 2012.
121. Raj KP, Zell JA, Rock CL, et al: Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer 108: 512-518, 2013.
122. Cipolla BG, Havouis R and Moulinoux JP: Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed Pharmacother 64: 363-368, 2010.